COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,362 Articles (22,803 medRxiv, 8,559 bioRxiv)

Most recent first Previous |  Page 890: Articles 8891-8900  | Next

Long COVID in Children and Adolescents: A Systematic Review and Meta-analyses.
Lopez-Leon, S., Wegman-Ostrosky, T., Ayuzo del Valle, N. C., Perelman, C., Sepulveda, R., Rebolledo, P. A., Cuapio, A., Villapol, S.
10.1101/2022.03.10.22272237 — Posted: 2022-03-13
Polymorphism in IFNAR contributes to glucocorticoid response and outcome in ARDS and COVID-19
Jalkanen, J., Khan, S., Elima, K., Huttunen, T., Wang, N., Hollmen, M., Elo, L., Jalkanen, S.
10.1101/2022.03.10.22272123 — Posted: 2022-03-13
Cov2clusters: genomic clustering of SARS-CoV-2 sequences
Sobkowiak, B., Kamelian, K., Zlosnik, J., Tyson, J., da Silva, A. G., Hoang, L., Prystajecky, N., Colijn, C.
10.1101/2022.03.10.22272213 — Posted: 2022-03-13
Time-Varying Death Risk After SARS-CoV-2-Infection in Swedish Long-Term Care Facilities
Ballin, M., Ioannidis, J. P. A., Bergman, J., Kivipelto, M., Nordström, A., Nordström, P.
10.1101/2022.03.10.22272097 — Posted: 2022-03-13
Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine - a prospective observational study
Herzberg, J., Fischer, B., Becher, H., Becker, A.-K., Honarpisheh, H., Guraya, S. Y., Strate, T., Knabbe, C.
10.1101/2022.03.10.22272204 — Posted: 2022-03-13
The changing impact of vaccines in the COVID-19 pandemic
Cohen, J. A., Stuart, R. M., Panovska-Griffiths, J., Mudimu, E., Abeysuriya, R. G., Kerr, C. C., Famulare, M., Klein, D. J.
10.1101/2022.03.10.22272222 — Posted: 2022-03-13
Disentangling the effect of measures, variants and vaccines on SARS-CoV-2 Infections in England: A dynamic intensity model
Boldea, O., Cornea-Madeira, A., Madeira, J.
10.1101/2022.03.09.22272165 — Posted: 2022-03-12
Long COVID and its associated factors among COVID survivors in the community from a middle-income country: an online cross-sectional study
Moy, F. M., Hairi, N. N., Lim, E. R. J., Bulgiba, A.
10.1101/2022.03.09.22272168 — Posted: 2022-03-12
Vaccine-induced antibody level predicts the clinical course of breakthrough infection of COVID-19 caused by delta and omicron variants: a prospective observational cohort study
Kim, M. H., Nam, Y., Son, N.-H., Heo, N., Kim, B., Kang, E., Shin, A., Yang, A. J., Park, Y. S., Kim, H., Kyong, T., Kim, Y. C.
10.1101/2022.03.09.22272171 — Posted: 2022-03-12
Identification and Quantification of Bioactive Compounds Suppressing SARS-CoV-2 Signals in Wastewater-based Epidemiology Surveillance
Bayati, M., Hsieh, H.-Y., Hsu, S.-Y., Rogers, E., Belenchia, A., Zemmer, S. A., Blanc, T., LePage, C., Klutts, J., Reynolds, M., Semkiw, E., Johnson, H.-Y., Foley, T., Wieberg, C. G., Wenzel, J., Lyddon, T., LePique, M., Rushford, C., Salcedo, B., Young, K., Graham, M., Suarez, R., Ford, A., Lei, Z., Sumner, L., Mooney, B. P., Wei, X., Greenlief, C. M., Johnson, M., Lin, C.-H.
10.1101/2022.03.09.22272155 — Posted: 2022-03-12

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).